Antitumor effects of a monoclonal antibody to human CCR9 in leukemia cell xenografts

References

• Cyster JG. Lymphoid organ development and cell migration. Immunol Rev 2003; 195:5 - 14; http://dx.doi.org/10.1034/j.1600-065X.2003.00075.x; PMID: 12969306
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 2011; 11:597 - 606; http://dx.doi.org/10.1038/nri3049; PMID: 21866172
   PubMed Web of Science ®Google Scholar
• Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ, Wang J. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 2010; 29:709 - 22; http://dx.doi.org/10.1007/s10555-010-9256-x; PMID: 20839032
   PubMed Web of Science ®Google Scholar
• Ben-Baruch A. Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis 2008; 25:345 - 56; http://dx.doi.org/10.1007/s10585-007-9097-3; PMID: 17891505
   PubMed Web of Science ®Google Scholar
• Letsch A, Keilholz U, Schadendorf D, Assfalg G, Asemissen AM, Thiel E, Scheibenbogen C. Functional CCR9 expression is associated with small intestinal metastasis. J Invest Dermatol 2004; 122:685 - 90; http://dx.doi.org/10.1111/j.0022-202X.2004.22315.x; PMID: 15086554
   PubMed Web of Science ®Google Scholar
• Richmond A. CCR9 homes metastatic melanoma cells to the small bowel. Clin Cancer Res 2008; 14:621 - 3; http://dx.doi.org/10.1158/1078-0432.CCR-07-2235; PMID: 18245518
   PubMed Web of Science ®Google Scholar
• Amersi FF, Terando AM, Goto Y, Scolyer RA, Thompson JF, Tran AN, Faries MB, Morton DL, Hoon DS. Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res 2008; 14:638 - 45; http://dx.doi.org/10.1158/1078-0432.CCR-07-2025; PMID: 18245522
   PubMed Web of Science ®Google Scholar
• Zaballos A, Gutiérrez J, Varona R, Ardavín C, Márquez G. Cutting edge: identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK. J Immunol 1999; 162:5671 - 5; PMID: 10229797
   PubMed Web of Science ®Google Scholar
• Youn BS, Kim CH, Smith FO, Broxmeyer HE. TECK, an efficacious chemoattractant for human thymocytes, uses GPR-9-6/CCR9 as a specific receptor. Blood 1999; 94:2533 - 6; PMID: 10498628
   PubMed Web of Science ®Google Scholar
• Wurbel MA, Philippe JM, Nguyen C, Victorero G, Freeman T, Wooding P, Miazek A, Mattei MG, Malissen M, Jordan BR, et al. The chemokine TECK is expressed by thymic and intestinal epithelial cells and attracts double- and single-positive thymocytes expressing the TECK receptor CCR9. Eur J Immunol 2000; 30:262 - 71; http://dx.doi.org/10.1002/1521-4141(200001)30:1<262::AID-IMMU262>3.0.CO;2-0; PMID: 10602049
   PubMed Web of Science ®Google Scholar
• Carramolino L, Zaballos A, Kremer L, Villares R, Martín P, Ardavín C, Martínez-A C, Márquez G. Expression of CCR9 beta-chemokine receptor is modulated in thymocyte differentiation and is selectively maintained in CD8(+) T cells from secondary lymphoid organs. Blood 2001; 97:850 - 7; http://dx.doi.org/10.1182/blood.V97.4.850; PMID: 11159507
   PubMed Web of Science ®Google Scholar
• Kunkel EJ, Campbell JJ, Haraldsen G, Pan J, Boisvert J, Roberts AI, Ebert EC, Vierra MA, Goodman SB, Genovese MC, et al. Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. J Exp Med 2000; 192:761 - 8; http://dx.doi.org/10.1084/jem.192.5.761; PMID: 10974041
   PubMed Web of Science ®Google Scholar
• Zabel BA, Agace WW, Campbell JJ, Heath HM, Parent D, Roberts AI, Ebert EC, Kassam N, Qin S, Zovko M, et al. Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. J Exp Med 1999; 190:1241 - 56; http://dx.doi.org/10.1084/jem.190.9.1241; PMID: 10544196
   PubMed Web of Science ®Google Scholar
• Wendland M, Czeloth N, Mach N, Malissen B, Kremmer E, Pabst O, Förster R. CCR9 is a homing receptor for plasmacytoid dendritic cells to the small intestine. Proc Natl Acad Sci U S A 2007; 104:6347 - 52; http://dx.doi.org/10.1073/pnas.0609180104; PMID: 17404233
   PubMed Web of Science ®Google Scholar
• Wurbel MA, Malissen M, Guy-Grand D, Meffre E, Nussenzweig MC, Richelme M, Carrier A, Malissen B. Mice lacking the CCR9 CC-chemokine receptor show a mild impairment of early T- and B-cell development and a reduction in T-cell receptor gammadelta(+) gut intraepithelial lymphocytes. Blood 2001; 98:2626 - 32; http://dx.doi.org/10.1182/blood.V98.9.2626; PMID: 11675330
   PubMed Web of Science ®Google Scholar
• Vicari AP, Figueroa DJ, Hedrick JA, Foster JS, Singh KP, Menon S, Copeland NG, Gilbert DJ, Jenkins NA, Bacon KB, et al. TECK: a novel CC chemokine specifically expressed by thymic dendritic cells and potentially involved in T cell development. Immunity 1997; 7:291 - 301; http://dx.doi.org/10.1016/S1074-7613(00)80531-2; PMID: 9285413
   PubMed Web of Science ®Google Scholar
• Qiuping Z, Qun L, Chunsong H, Xiaolian Z, Baojun H, Mingzhen Y, Chengming L, Jinshen H, Qingping G, Kejian Z, et al. Selectively increased expression and functions of chemokine receptor CCR9 on CD4+ T cells from patients with T-cell lineage acute lymphocytic leukemia. Cancer Res 2003; 63:6469 - 77; PMID: 14559839
   PubMed Web of Science ®Google Scholar
• Singh S, Singh UP, Stiles JK, Grizzle WE, Lillard JW Jr.. Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin Cancer Res 2004; 10:8743 - 50; http://dx.doi.org/10.1158/1078-0432.CCR-04-0266; PMID: 15623660
   PubMed Web of Science ®Google Scholar
• Johnson-Holiday C, Singh R, Johnson E, Singh S, Stockard CR, Grizzle WE, Lillard JW Jr.. CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion. Int J Oncol 2011; 38:1279 - 85; PMID: 21344163
   PubMed Web of Science ®Google Scholar
• Sharma PK, Singh R, Novakovic KR, Eaton JW, Grizzle WE, Singh S. CCR9 mediates PI3K/AKT-dependent antiapoptotic signals in prostate cancer cells and inhibition of CCR9-CCL25 interaction enhances the cytotoxic effects of etoposide. Int J Cancer 2010; 127:2020 - 30; http://dx.doi.org/10.1002/ijc.25219; PMID: 20127861
   PubMed Web of Science ®Google Scholar
• Johnson EL, Singh R, Johnson-Holiday CM, Grizzle WE, Partridge EE, Lillard JW Jr., Singh S. CCR9 interactions support ovarian cancer cell survival and resistance to cisplatin-induced apoptosis in a PI3K-dependent and FAK-independent fashion. J Ovarian Res 2010; 3:15; http://dx.doi.org/10.1186/1757-2215-3-15; PMID: 20565782
   PubMedGoogle Scholar
• Qiuping Z, Jei X, Youxin J, Wei J, Chun L, Jin W, Qun W, Yan L, Chunsong H, Mingzhen Y, et al. CC chemokine ligand 25 enhances resistance to apoptosis in CD4+ T cells from patients with T-cell lineage acute and chronic lymphocytic leukemia by means of livin activation. Cancer Res 2004; 64:7579 - 87; http://dx.doi.org/10.1158/0008-5472.CAN-04-0641; PMID: 15492285
   PubMed Web of Science ®Google Scholar
• Mirandola L, Chiriva-Internati M, Montagna D, Locatelli F, Zecca M, Ranzani M, Basile A, Locati M, Cobos E, Kast WM, et al. Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. J Pathol 2012; 226:713 - 22; http://dx.doi.org/10.1002/path.3015; PMID: 21984373
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhang L, Wu R, Han R, Jia Y, Jiang Z, Cheng M, Gan J, Tao X, Zhang Q. Specific killing of CCR9 high-expressing acute T lymphocytic leukemia cells by CCL25 fused with PE38 toxin. Leuk Res 2011; 35:1254 - 60; http://dx.doi.org/10.1016/j.leukres.2011.01.015; PMID: 21295855
   PubMed Web of Science ®Google Scholar
• Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317 - 27; http://dx.doi.org/10.1038/nri2744; PMID: 20414205
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278 - 87; http://dx.doi.org/10.1038/nrc3236; PMID: 22437872
   PubMed Web of Science ®Google Scholar
• Reichert JM, Dhimolea E. The future of antibodies as cancer drugs. Drug Discov Today 2012; 17:954 - 63; http://dx.doi.org/10.1016/j.drudis.2012.04.006; PMID: 22561895
   PubMed Web of Science ®Google Scholar
• Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 1990; 82:4 - 6; http://dx.doi.org/10.1093/jnci/82.1.4; PMID: 1688381
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249 - 57; http://dx.doi.org/10.1038/35025220; PMID: 11001068
   PubMed Web of Science ®Google Scholar
• Meert AP, Paesmans M, Martin B, Delmotte P, Berghmans T, Verdebout JM, Lafitte JJ, Mascaux C, Sculier JP. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2002; 87:694 - 701; http://dx.doi.org/10.1038/sj.bjc.6600551; PMID: 12232748
   PubMed Web of Science ®Google Scholar
• Seidel UJ, Schlegel P, Lang P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol 2013; 4:76; http://dx.doi.org/10.3389/fimmu.2013.00076; PMID: 23543707
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443 - 6; http://dx.doi.org/10.1038/74704; PMID: 10742152
   PubMed Web of Science ®Google Scholar
• Singh R, Stockard CR, Grizzle WE, Lillard JW Jr., Singh S. Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer. Int J Oncol 2011; 39:373 - 81; PMID: 21637913
   PubMed Web of Science ®Google Scholar
• Shen X, Mailey B, Ellenhorn JD, Chu PG, Lowy AM, Kim J. CC chemokine receptor 9 enhances proliferation in pancreatic intraepithelial neoplasia and pancreatic cancer cells. J Gastrointest Surg 2009; 13:1955 - 62, discussion 1962; http://dx.doi.org/10.1007/s11605-009-1002-8; PMID: 19756884
   PubMed Web of Science ®Google Scholar
• Szpakowska M, Fievez V, Arumugan K, van Nuland N, Schmit JC, Chevigné A. Function, diversity and therapeutic potential of the N-terminal domain of human chemokine receptors. Biochem Pharmacol 2012; 84:1366 - 80; http://dx.doi.org/10.1016/j.bcp.2012.08.008; PMID: 22935450
   PubMed Web of Science ®Google Scholar
• Rajagopalan L, Rajarathnam K. Structural basis of chemokine receptor function--a model for binding affinity and ligand selectivity. Biosci Rep 2006; 26:325 - 39; http://dx.doi.org/10.1007/s10540-006-9025-9; PMID: 17024562
   PubMed Web of Science ®Google Scholar
• Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, Mendelsohn M, Charron J, Datta M, Young F, Stall AM, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992; 68:855 - 67; http://dx.doi.org/10.1016/0092-8674(92)90029-C; PMID: 1547487
   PubMed Web of Science ®Google Scholar
• Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91:1644 - 52; PMID: 9473230
   PubMed Web of Science ®Google Scholar
• Johnson-Holiday C, Singh R, Johnson EL, Grizzle WE, Lillard JW Jr., Singh S. CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion. World J Surg Oncol 2011; 9:46; http://dx.doi.org/10.1186/1477-7819-9-46; PMID: 21539750
   PubMed Web of Science ®Google Scholar
• Bezombes C, Fournié JJ, Laurent G. Direct effect of rituximab in B-cell-derived lymphoid neoplasias: mechanism, regulation, and perspectives. Mol Cancer Res 2011; 9:1435 - 42; http://dx.doi.org/10.1158/1541-7786.MCR-11-0154; PMID: 21921050
   PubMed Web of Science ®Google Scholar
• Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, Sotto JJ, Leroux D, Bensa JC, Plumas J. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101:949 - 54; http://dx.doi.org/10.1182/blood-2002-02-0469; PMID: 12393572
   PubMed Web of Science ®Google Scholar
• van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 2006; 12:4027 - 35; http://dx.doi.org/10.1158/1078-0432.CCR-06-0066; PMID: 16818702
   PubMed Web of Science ®Google Scholar
• Bertolini F, Dell’Agnola C, Mancuso P, Rabascio C, Burlini A, Monestiroli S, Gobbi A, Pruneri G, Martinelli G. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin’s lymphoma. Cancer Res 2002; 62:3106 - 12; PMID: 12036921
   PubMed Web of Science ®Google Scholar
• Kuhne MR, Mulvey T, Belanger B, Chen S, Pan C, Chong C, Cao F, Niekro W, Kempe T, Henning KA, et al. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res 2013; 19:357 - 66; http://dx.doi.org/10.1158/1078-0432.CCR-12-2333; PMID: 23213054
   PubMed Web of Science ®Google Scholar
• Ito Y, Miyamoto T, Chong Y, Aoki T, Kato K, Akashi K, Kamimura T. Successful treatment with anti-CC chemokine receptor 4 MoAb of relapsed adult T-cell leukemia/lymphoma after umbilical cord blood transplantation. Bone Marrow Transplant 2013; 48:998 - 9; http://dx.doi.org/10.1038/bmt.2012.268; PMID: 23292237
   PubMed Web of Science ®Google Scholar
• Carramolino L, Kremer L, Goya I, Varona R, Buesa JM, Gutiérrez J, Zaballos A, Martínez-A C, Márquez G. Down-regulation of the beta-chemokine receptor CCR6 in dendritic cells mediated by TNF-alpha and IL-4. J Leukoc Biol 1999; 66:837 - 44; PMID: 10577517
   PubMed Web of Science ®Google Scholar
• Goya I, Gutiérrez J, Varona R, Kremer L, Zaballos A, Márquez G. Identification of CCR8 as the specific receptor for the human beta-chemokine I-309: cloning and molecular characterization of murine CCR8 as the receptor for TCA-3. J Immunol 1998; 160:1975 - 81; PMID: 9469461
   PubMed Web of Science ®Google Scholar
• Martín-Gayo E, Sierra-Filardi E, Corbí AL, Toribio ML. Plasmacytoid dendritic cells resident in human thymus drive natural Treg cell development. Blood 2010; 115:5366 - 75; http://dx.doi.org/10.1182/blood-2009-10-248260; PMID: 20357241
   PubMed Web of Science ®Google Scholar
• Kremer L, Márquez G. Generation of monoclonal antibodies against chemokine receptors. Methods Mol Biol 2004; 239:243 - 60; PMID: 14573924
   PubMedGoogle Scholar